Scott Naturman is a corporate
partner in Hughes Hubbard’s New York office. His practice primarily
focuses on counseling corporate clients, including public and private companies
and private equity firms, with respect to mergers and acquisitions matters.
Scott has broad experience representing U.S. and international clients
operating in various industries including life sciences, technology, energy and
Prior to joining Hughes
Hubbard, Scott was a special counsel at Covington & Burling LLP in its Corporate
Practice Group. He represented a variety of clients in the purchase and sale of
public and private companies and their assets. Scott began his career as an
associate at Simpson Thacher & Bartlett in the Mergers and Acquisitions
Group. His experience covers counseling clients in mergers and acquisitions,
divestitures, private equity transactions, joint ventures, and other general
Selected as a top-rated lawyer in New York Super Lawyers magazine for Mergers & Acquisitions (2020, 2021)
Representation of Santander Consumer USA Holdings Inc. (SC), in its pending sale to parent company and majority shareholder Santander Holdings USA Inc. (SHUSA) in a $2.5 billion deal that will take the Dallas-based auto lending and consumer finance company private
Representation of SPAC Isos Acquisition Corp. in its $2.6 billion IPO merger with Bowlero Corp. that took the world’s largest owner and operator of bowling centers public
Representation of Mill Rock Capital in its investment in the Execu/Search Group
Representation of Mill Rock Capital in its strategic growth investment in DRT Holdings, Inc.
Representation of ICV in its investment in Mintz Group
Representation of Piramal Enterprises Limited in its $950 million sale of Decision Resources Group
Representation of Elbit in its acquisition of Sparton
Representation of Orbia (f/k/a Mexichem) in its $1.8 billion acquisition of Netafim Ltd., a global technology and industrial company based in Israel
Representation of TE Connectivity in a cross border, carve-out acquisition from ABB
Representation of Johnson & Johnson in its sale of RoC Skincare
Representation of Sensyne Health plc in its exclusive strategic collaboration with, and a $10 million equity investment in, Phesi, Inc, a U.S.-based specialist clinical trials data company, and its £27.5 million equity fundraising
Representation of Renesas Electronics Corporation on its $4.9 billion recommended cash offer for Dialog Semiconductor PLC
Representation of Stryker Corporation in its acquisition of Novadaq Technologies, Inc.
Representation of Fiberon in its $470 million sale to Fortune Brands Home & Security
Representation of Reliance Industries Limited in its $75 million acquisition of Radisys Corporation
Representation of Illumina in its announced $1.2 billion acquisition of Pacific Biosciences
Representation of Eisai Co., Ltd. and Eisai Inc. on the acquisition of all global development and marketing rights for the chronic weight management treatment lorcaserin hydrochloride (BELVIQ) from Arena Pharmaceuticals, Inc.
Representation of Altice in the $1 billion co-investment by funds advised by BC Partners and Canada Pension Plan Investment Board in Cablevision Systems Corporation
Representation of European telecommunications company Altice S.A. in a $9.1 billion transaction to acquire a controlling stake in Suddenlink, the seventh largest cable operator in the U.S.
Representation of Johnson & Johnson in the sale of its global Splenda business to Heartland Food Products Group and Centerbridge Partners LP
Representation of Famy Care Limited in the $750 million sale of its women's health business to Mylan Laboratories Limited
Representation of Gannett Broadcasting in its formation and broadcasting of the Justice Network, a digital multicast channel devoted to law enforcement-related programming
Representation of ITOCHU Corporation and ITOCHU International Inc. in the sale of PrimeSource Building Products, Inc., a North American distributor of building materials, to Platinum Equity
Representation of Resource America in its credit management joint venture with CVC Capital Partners
Representation of Ascension in a $200 million investment in preferred stock of Accretive Health